JP2021038250A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021038250A5 JP2021038250A5 JP2020193269A JP2020193269A JP2021038250A5 JP 2021038250 A5 JP2021038250 A5 JP 2021038250A5 JP 2020193269 A JP2020193269 A JP 2020193269A JP 2020193269 A JP2020193269 A JP 2020193269A JP 2021038250 A5 JP2021038250 A5 JP 2021038250A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- micrograms
- medicament according
- varenicline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022202809A JP7502404B2 (ja) | 2014-10-20 | 2022-12-20 | 眼の病状の治療方法 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462066280P | 2014-10-20 | 2014-10-20 | |
| US62/066,280 | 2014-10-20 | ||
| US201562100844P | 2015-01-07 | 2015-01-07 | |
| US62/100,844 | 2015-01-07 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017539528A Division JP6873906B2 (ja) | 2014-10-20 | 2015-10-19 | 眼の病状の治療方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022202809A Division JP7502404B2 (ja) | 2014-10-20 | 2022-12-20 | 眼の病状の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021038250A JP2021038250A (ja) | 2021-03-11 |
| JP2021038250A5 true JP2021038250A5 (https=) | 2021-11-11 |
| JP7257371B2 JP7257371B2 (ja) | 2023-04-13 |
Family
ID=55748136
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017539528A Active JP6873906B2 (ja) | 2014-10-20 | 2015-10-19 | 眼の病状の治療方法 |
| JP2020193269A Active JP7257371B2 (ja) | 2014-10-20 | 2020-11-20 | 眼の病状の治療方法 |
| JP2022202809A Active JP7502404B2 (ja) | 2014-10-20 | 2022-12-20 | 眼の病状の治療方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017539528A Active JP6873906B2 (ja) | 2014-10-20 | 2015-10-19 | 眼の病状の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022202809A Active JP7502404B2 (ja) | 2014-10-20 | 2022-12-20 | 眼の病状の治療方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (14) | US9532944B2 (https=) |
| EP (3) | EP3209295B2 (https=) |
| JP (3) | JP6873906B2 (https=) |
| KR (2) | KR102511955B1 (https=) |
| CN (3) | CN111956803B (https=) |
| AU (2) | AU2015336216B2 (https=) |
| BR (2) | BR122022025737B1 (https=) |
| CA (1) | CA2965129C (https=) |
| DK (2) | DK3848028T5 (https=) |
| EA (1) | EA035335B1 (https=) |
| ES (2) | ES2848977T5 (https=) |
| FI (1) | FI3848028T3 (https=) |
| IL (3) | IL293188B2 (https=) |
| MX (2) | MX392383B (https=) |
| MY (1) | MY186870A (https=) |
| PH (1) | PH12017500602A1 (https=) |
| PL (1) | PL3848028T3 (https=) |
| PT (2) | PT3209295T (https=) |
| SG (2) | SG10202011669PA (https=) |
| WO (1) | WO2016064759A1 (https=) |
| ZA (1) | ZA201703467B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202011669PA (en) | 2014-10-20 | 2020-12-30 | Oyster Point Pharma Inc | Methods of treating ocular conditions |
| CN109310692B (zh) * | 2016-04-07 | 2022-01-25 | 奥伊斯特普安生物制药公司 | 治疗眼部病状的方法 |
| TW202019417A (zh) * | 2018-07-10 | 2020-06-01 | 美商奧伊斯特普安生物製藥公司 | 治療眼部症狀之正向異位調節劑與菸鹼乙醯膽鹼受體促效劑之組合 |
| TW202019424A (zh) * | 2018-07-10 | 2020-06-01 | 美商奧伊斯特普安生物製藥公司 | 治療眼部症狀之方法 |
| ES3039903T3 (en) * | 2020-04-28 | 2025-10-27 | Oyster Point Pharma Inc | Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections |
| WO2025037323A1 (en) * | 2023-08-12 | 2025-02-20 | Pavan Kumar Kothapuvari | Pharmaceutical compositions for treatment of dry eye disease and associated disorders |
| DE102023208057A1 (de) * | 2023-08-23 | 2025-02-27 | Ursapharm Arzneimittel Gmbh | Ophthalmologische zusammensetzung enthaltend mindestens einen nikotinischen acetylcholinrezeptor-agonist zur topischen applikation am auge bei der prävention oder behandlung von entzündungen am auge |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6277855B1 (en) * | 2000-04-21 | 2001-08-21 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with nicotinic acetylcholine receptor agonists |
| US20030008892A1 (en) | 2001-07-09 | 2003-01-09 | Pfizer Inc. | Pharmaceutical composition and method of modulating cholinergic function in a mammal |
| EP1461040B1 (en) | 2001-11-29 | 2006-03-15 | Pfizer Products Inc. | Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof |
| WO2004039366A1 (en) * | 2002-11-01 | 2004-05-13 | Pharmacia & Upjohn Company Llc | Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy |
| US20060270592A1 (en) * | 2004-03-19 | 2006-11-30 | Ophthalmic Research Associates, Inc. | Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions |
| MX2007004495A (es) * | 2004-10-15 | 2007-05-10 | Pfizer Prod Inc | Composiciones y procedimientos para la administracion intranasal, bucal, sublingual y pulmonar de vareniclina. |
| EP1929996B1 (en) * | 2004-11-09 | 2011-02-16 | Novagali Pharma S.A. | Ophthalmic emulsions containing an immunosuppressive agent |
| WO2006100075A2 (en) * | 2005-03-22 | 2006-09-28 | Niconovum Ab | Use of an artificial sweetener to enhance absorption of nicotine |
| US20110086086A1 (en) | 2005-07-26 | 2011-04-14 | Pfizer Inc | Transdermal system for varenicline |
| CA2620202C (en) | 2005-08-26 | 2016-10-04 | The Board Of Trustees Of The Leland Stanford Junior University | Therapy procedure for drug delivery for trigeminal pain |
| US8182840B2 (en) | 2005-09-27 | 2012-05-22 | Tissue Tech, Inc. | Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition |
| TWI405763B (zh) | 2006-11-02 | 2013-08-21 | Targacept Inc | 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺 |
| US20080132475A1 (en) * | 2006-12-05 | 2008-06-05 | Charles Gerald Connor | Treatment for dry eye |
| AU2008211613B2 (en) * | 2007-02-02 | 2013-05-23 | Pfizer Products Inc. | Tricyclic compounds and their use as glucocorticoid receptor modulators |
| EP2322168A1 (en) * | 2007-04-02 | 2011-05-18 | Parkinson's Institute | Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments |
| US20090093446A1 (en) | 2007-10-05 | 2009-04-09 | Winston Laboratories, Inc. | Method for alleviating keratoconjunctivitis sicca |
| CL2008003507A1 (es) * | 2007-11-26 | 2009-11-27 | Neuroderm Ltd | Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico. |
| US20090215787A1 (en) | 2008-02-22 | 2009-08-27 | Mai De Ltd. | Preparations of new polymorphic forms of varenicline tartrate |
| JP2011513421A (ja) | 2008-03-05 | 2011-04-28 | ターガセプト，インコーポレイテッド | サブタイプ選択的なジアザビシクロアルカンのアミド |
| WO2010028033A1 (en) | 2008-09-05 | 2010-03-11 | Targacept, Inc. | Amides of diazabicyclooctanes and uses thereof |
| WO2010028011A1 (en) | 2008-09-05 | 2010-03-11 | Targacept, Inc. | Amides of diazabicyclononanes and uses thereof |
| PL3279195T3 (pl) | 2008-12-01 | 2020-12-14 | Oyster Point Pharma, Inc. | Synteza i nowe postacie soli (R)-5-((E)-2-pirolidyn-3-ylowinylo)pirymidyny |
| US9145396B2 (en) | 2008-12-01 | 2015-09-29 | Targacept, Inc. | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine |
| GB2470833B (en) | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
| US20110274628A1 (en) | 2010-05-07 | 2011-11-10 | Borschke August J | Nicotine-containing pharmaceutical compositions |
| US8821457B2 (en) * | 2010-09-08 | 2014-09-02 | Johnson & Johnson Vision Care, Inc. | Punctal plug containing drug formulation |
| US20140170157A1 (en) * | 2011-06-15 | 2014-06-19 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of selecting therapeutic indications |
| KR20140027939A (ko) * | 2011-06-30 | 2014-03-07 | 도레이 카부시키가이샤 | 지양제 |
| JP6162705B2 (ja) * | 2011-10-20 | 2017-07-12 | ノバルティス アーゲー | アルファ７ニコチン性アセチルコリン受容体活性化剤による処置に対する応答性を予測するバイオマーカー |
| CN104094114A (zh) * | 2011-11-30 | 2014-10-08 | 黛尔格诺斯蒂尔有限公司 | 干眼诊断 |
| ES2426517B1 (es) * | 2012-04-20 | 2014-05-14 | Genetracer Biotech S.L | Método para predecir la seguridad de un tratamiento farmacológico |
| ES2649730T3 (es) | 2013-03-15 | 2018-01-15 | Glia Llc | Distribución craneal de compuestos farmacéuticos |
| EP2986339A4 (en) | 2013-04-19 | 2016-12-21 | Oculeve Inc | Nasal stimulation devices and methods |
| SG10202011669PA (en) | 2014-10-20 | 2020-12-30 | Oyster Point Pharma Inc | Methods of treating ocular conditions |
| CN109310692B (zh) | 2016-04-07 | 2022-01-25 | 奥伊斯特普安生物制药公司 | 治疗眼部病状的方法 |
| TW202019417A (zh) | 2018-07-10 | 2020-06-01 | 美商奧伊斯特普安生物製藥公司 | 治療眼部症狀之正向異位調節劑與菸鹼乙醯膽鹼受體促效劑之組合 |
| TW202019424A (zh) | 2018-07-10 | 2020-06-01 | 美商奧伊斯特普安生物製藥公司 | 治療眼部症狀之方法 |
-
2015
- 2015-10-19 SG SG10202011669PA patent/SG10202011669PA/en unknown
- 2015-10-19 PT PT158523407T patent/PT3209295T/pt unknown
- 2015-10-19 BR BR122022025737-2A patent/BR122022025737B1/pt active IP Right Grant
- 2015-10-19 EP EP15852340.7A patent/EP3209295B2/en active Active
- 2015-10-19 CN CN202010304375.2A patent/CN111956803B/zh active Active
- 2015-10-19 KR KR1020177013534A patent/KR102511955B1/ko active Active
- 2015-10-19 US US14/887,253 patent/US9532944B2/en active Active
- 2015-10-19 ES ES15852340T patent/ES2848977T5/es active Active
- 2015-10-19 DK DK20212556.3T patent/DK3848028T5/da active
- 2015-10-19 ES ES20212556T patent/ES2986830T3/es active Active
- 2015-10-19 EP EP24171017.7A patent/EP4413974A3/en active Pending
- 2015-10-19 KR KR1020237009057A patent/KR102601505B1/ko active Active
- 2015-10-19 EA EA201790893A patent/EA035335B1/ru unknown
- 2015-10-19 US US14/887,243 patent/US9504644B2/en active Active
- 2015-10-19 CN CN201580067940.5A patent/CN107106542B/zh active Active
- 2015-10-19 CA CA2965129A patent/CA2965129C/en active Active
- 2015-10-19 CN CN202010304809.9A patent/CN111956650B/zh active Active
- 2015-10-19 IL IL293188A patent/IL293188B2/en unknown
- 2015-10-19 IL IL318427A patent/IL318427A/en unknown
- 2015-10-19 US US14/887,259 patent/US9504645B2/en active Active
- 2015-10-19 BR BR112017008097-4A patent/BR112017008097B1/pt active IP Right Grant
- 2015-10-19 US US14/887,248 patent/US9597284B2/en active Active
- 2015-10-19 WO PCT/US2015/056273 patent/WO2016064759A1/en not_active Ceased
- 2015-10-19 FI FIEP20212556.3T patent/FI3848028T3/fi active
- 2015-10-19 AU AU2015336216A patent/AU2015336216B2/en active Active
- 2015-10-19 EP EP20212556.3A patent/EP3848028B9/en active Active
- 2015-10-19 PL PL20212556.3T patent/PL3848028T3/pl unknown
- 2015-10-19 PT PT202125563T patent/PT3848028T/pt unknown
- 2015-10-19 DK DK15852340.7T patent/DK3209295T4/da active
- 2015-10-19 IL IL251769A patent/IL251769B/en unknown
- 2015-10-19 SG SG11201703135XA patent/SG11201703135XA/en unknown
- 2015-10-19 JP JP2017539528A patent/JP6873906B2/ja active Active
- 2015-10-19 MY MYPI2017701382A patent/MY186870A/en unknown
- 2015-10-19 MX MX2017005064A patent/MX392383B/es unknown
-
2017
- 2017-02-01 US US15/422,382 patent/US10456396B2/en active Active
- 2017-03-31 PH PH12017500602A patent/PH12017500602A1/en unknown
- 2017-04-19 MX MX2022005888A patent/MX2022005888A/es unknown
- 2017-05-19 ZA ZA2017/03467A patent/ZA201703467B/en unknown
-
2019
- 2019-09-10 US US16/566,237 patent/US11224598B2/en active Active
-
2020
- 2020-08-06 AU AU2020213351A patent/AU2020213351B2/en active Active
- 2020-11-20 JP JP2020193269A patent/JP7257371B2/ja active Active
-
2021
- 2021-12-06 US US17/543,505 patent/US11903941B2/en active Active
-
2022
- 2022-12-20 JP JP2022202809A patent/JP7502404B2/ja active Active
-
2023
- 2023-03-23 US US18/125,551 patent/US11911380B2/en active Active
- 2023-03-23 US US18/125,562 patent/US11903943B2/en active Active
- 2023-03-23 US US18/125,517 patent/US11903942B2/en active Active
-
2024
- 2024-01-26 US US18/423,908 patent/US20240173318A1/en not_active Abandoned
-
2025
- 2025-04-03 US US19/169,817 patent/US20250235449A1/en active Pending
- 2025-04-03 US US19/169,843 patent/US12576080B2/en active Active
- 2025-04-03 US US19/169,836 patent/US20250275963A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021038250A5 (https=) | ||
| JP2023024574A5 (https=) | ||
| Jünemann et al. | Drug bioavailability from topically applied ocular drops. Does drop size matter? | |
| US10406203B2 (en) | Ophthalmic treatment composition and vehicle for delivery of pharmaceutical substances or therapeutic agents | |
| JP2022120125A5 (https=) | ||
| JP7502404B2 (ja) | 眼の病状の治療方法 | |
| JPH0269413A (ja) | アレルギー性鼻炎の治療方法 | |
| JPH0977656A (ja) | 点眼用エアゾル組成物 | |
| US20260014196A1 (en) | Compositions of molecular hydrogen, oxyhydrogen and therapeutic uses thereof | |
| Felicilda Reynaldo et al. | Evidence-Based Pharmacotherapy for Dry Eye Disease, Part 2 | |
| US20200222512A9 (en) | Topical Ocular Preparation of Botulinum Toxin for Use in Ocular Surface Disease | |
| Elliott et al. | Varenicline Nasal Spray (Tyrvaya) | |
| Sahoo et al. | Mucoadhesive nanopolymers for posterior segment drug delivery | |
| US20200093887A1 (en) | Ophthalmic treatment composition and vehicle for delivery of pharmaceutical substances or therapeutic agents | |
| US20070071835A1 (en) | Administering pharmaceutical compositions to the mammalian central nervous system | |
| CA2560798A1 (en) | Administering pharmaceutical compositions to the mammalian central nervous system |